These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32355298)

  • 1. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
    Liao Y; Liao Y; Li J; Xiong J; Fan Y
    Sci Rep; 2020 Apr; 10(1):7349. PubMed ID: 32355298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in
    Liao Y; Liao Y; Li J; Li J; Fan Y; Xu B
    Cancer Manag Res; 2018; 10():3801-3808. PubMed ID: 30288111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
    Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
    Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
    Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
    Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
    Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
    Lee J; Kim HH; Ro SM; Yang JH
    PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
    Mullan PB; Bingham V; Haddock P; Irwin GW; Kay E; McQuaid S; Buckley NE
    BMC Cancer; 2019 Apr; 19(1):236. PubMed ID: 30935371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer].
    Hao XP; Jiang ZF
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):101-103. PubMed ID: 33378800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Singareeka Raghavendra A; Liu D; Shen Y; Barcenas CH; Ueno NT; Giordano S; Tripathy D; Sri Karuturi M
    Breast Cancer Res Treat; 2024 Aug; 207(1):81-90. PubMed ID: 38916821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.